VRPX vs. SPRC, CMRA, SBFM, BLPH, EVFM, HSTO, SXTC, ADTX, BPTH, and ALLR
Should you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include SciSparc (SPRC), Comera Life Sciences (CMRA), Sunshine Biopharma (SBFM), Bellerophon Therapeutics (BLPH), Evofem Biosciences (EVFM), Histogen (HSTO), China SXT Pharmaceuticals (SXTC), Aditxt (ADTX), Bio-Path (BPTH), and Allarity Therapeutics (ALLR). These companies are all part of the "pharmaceutical preparations" industry.
Virpax Pharmaceuticals (NASDAQ:VRPX) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk.
SciSparc's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.
In the previous week, Virpax Pharmaceuticals had 2 more articles in the media than SciSparc. MarketBeat recorded 6 mentions for Virpax Pharmaceuticals and 4 mentions for SciSparc. SciSparc's average media sentiment score of 1.58 beat Virpax Pharmaceuticals' score of 0.40 indicating that SciSparc is being referred to more favorably in the news media.
32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 6.2% of Virpax Pharmaceuticals shares are held by insiders. Comparatively, 1.5% of SciSparc shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Virpax Pharmaceuticals and SciSparc both received 2 outperform votes by MarketBeat users.
Virpax Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, SciSparc has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.
SciSparc has higher revenue and earnings than Virpax Pharmaceuticals.
Summary
SciSparc beats Virpax Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
Get Virpax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virpax Pharmaceuticals Competitors List
Related Companies and Tools
